An extension study to assess the long-term safety and efficacy of a triple combination therapy of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in children with cystic fibrosis who are at least 1 year old.
Descrizione riassuntiva dello studio
The aim of this extension study (VX22-445-123) is to assess the long-term safety and efficacy of a triple combination therapy of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in children with cystic fibrosis who are at least 1 year old. Participation in this study lasts just under two years. All participants receive the investigational drug, and both the parents/legal guardians of the participating children and the investigator know the administered dose. The insights gained from this study may be helpful in the future for the treatment of cystic fibrosis or other diseases and deepen scientific understanding.
(BASEC)
Intervento studiato
In this study, the term "investigational drug" refers to the triple combination of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA). ELX/TEZ/IVA is approved in some countries for use in certain patients with cystic fibrosis, and the researchers believe it may also be beneficial for younger age groups.
Even though the investigational drug was used in the main study (VX22-445-122), it is considered an investigational drug for this age group, meaning it has not yet been approved by some health authorities and is still being studied regarding long-term safety and efficacy for patients in this age group.
Participants in this study will receive one of four possible doses of the investigational drug based on their body weight. The dose may be adjusted if body weight changes during the treatment period.
Participation in the study lasts approximately 100 weeks (up to 96 weeks for the study treatment period and up to 4 weeks for the safety follow-up period).
Overall, participants, accompanied by parents, will come to the clinic at least 11 times over a period of 23 months. A study visit may last from 30 minutes to 4 hours. After 25 months, participation in the study is completed.
(BASEC)
Malattie studiate
This study (extension study, VX22-445-123) targets children who are at least 1 year old, suffer from cystic fibrosis, and have participated in the main study (VX22-445-122).
(BASEC)
1. The parents or legal guardian of the participating child have signed an informed consent form to participate. 2. At the discretion of the investigator, the parents or guardian must be able to understand the study requirements, restrictions, and instructions, and ensure that the child adheres to the study requirements and that the study is likely to be completed as planned. 3. The informed consent form was not revoked for the main study (VX22-445-122). (BASEC)
Criteri di esclusione
1. A disease or clinical condition has occurred in the participating child that could distort the study results or pose an additional risk during the administration of the investigational drug(s), such as liver cirrhosis, solid organ or hematological transplantation, cancer. 2. A drug intolerance occurred in the participating child in the main study VX22-445-122 that would expose the participating child to an additional risk. 3. Current participation in another clinical study other than the main study VX22-445-122. 4. Poor adherence to the investigational drug and/or does not follow the procedures in the main study VX22-445-122 according to the investigator's opinion. (BASEC)
Luogo dello studio
Berna, Zurigo
(BASEC)
Sponsor
Vertex Pharmaceuticals (CH) GmbH
(BASEC)
Contatto per ulteriori informazioni sullo studio
Persona di contatto in Svizzera
Prof. Dr. Alexander Möller
+41442667079
alexander.moeller@clutterkispi.uzh.chUniversitäts-Kinderspital Zürich, Pädiatrie, pädiatrische Pneumologie, Schlafmedizin (SSSSC)
(BASEC)
Informazioni scientifiche
non disponibile
Nome del comitato etico approvante (per studi multicentrici solo il comitato principale)
Commissione etica Zurigo
(BASEC)
Data di approvazione del comitato etico
29.10.2024
(BASEC)
ID di studio ICTRP
non disponibile
Titolo ufficiale (approvato dal comitato etico)
Eine offene Phase-III-Studie zur Beurteilung der Langzeitsicherheit und -wirksamkeit von Elexacaftor/Tezacaftor/Ivacaftor bei Mukoviszidose-Patienten ab 12 Monaten (BASEC)
Titolo accademico
non disponibile
Titolo pubblico
non disponibile
Malattie studiate
non disponibile
Intervento studiato
non disponibile
Tipo di studio
non disponibile
Disegno dello studio
non disponibile
Criteri di inclusione/esclusione
non disponibile
non disponibile
Endpoint primari e secondari
non disponibile
non disponibile
Data di registrazione
non disponibile
Inclusione del primo partecipante
non disponibile
Sponsor secondari
non disponibile
Contatti aggiuntivi
non disponibile
ID secondari
non disponibile
Risultati-Dati individuali dei partecipanti
non disponibile
Ulteriori informazioni sullo studio
non disponibile
Risultati dello studio
Riepilogo dei risultati
non disponibile
Link ai risultati nel registro primario
non disponibile